It is now clear that the nephrology community has reached a consensus regarding the arteriovenous fistula (AVF)—it is the preferred dialysis access for hemodialysis patients. Indeed, an increasingly ...

Neither omega-3 fatty acids from fish nor aspirin prevented failure of arteriovenous fistulae (AVFs) in patients receiving hemodialysis, according to results of a new study published online January 3 ...

In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...

This requires durable access to a blood vessel site where the dialysis machine can remove and return blood. Such access is created when a surgeon attaches a vein to an artery in the patient. The ...

An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...

Please provide your email address to receive an email when new articles are posted on . Among patients with kidney failure who successfully used a permanent access for hemodialysis, the incidence of ...

The MarketWatch News Department was not involved in the creation of this content. -- CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous ...

Humacyte, Inc. announced the results of its V007 Pivotal Phase 3 clinical trial for its acellular tissue engineered vessel (ATEV™), focused on arteriovenous access in patients with end-stage renal ...

BIRMINGHAM, Ala. – More than 600,000 people in the United States have end-stage kidney disease, and about 450,000 are kept alive through chronic hemodialysis to remove waste products from their blood.